RPE65 and Leber congenital amaurosis: Currently, an approved treatment is Voretigene neparvovec-rzyl, a viral vector mediated gene therapy approved for RPE65-mediated IRD, which accounts for about 2% of autosomal recessive RP and 16% of LCA (17, 18).